A multilocus SNP genotyping method for Mycoplasma pneumoniae
A technology for Mycoplasma pneumoniae and genotyping, which is applied in the fields of biochemical equipment and methods, recombinant DNA technology, and microbial determination/examination, and can solve the problems of incompatibility of typing results, complicated MLST operation, and limited discrimination ability. Achieve the effect of accurate typing, high resolution capability and strong discrimination
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 128
[0028] Example 1 Gene sequence comparison of 28 strains of Mycoplasma pneumoniae whole gene sequenced strains
[0029] The Illumina Hiseq 2000 whole-genome sequencing data of 20 different types of domestic Mycoplasma pneumoniae clinical isolates in our laboratory were compared with the whole-genome sequences of 49 strains of Mycoplasma pneumoniae in the NCBI database using Mauve software for whole-genome sequence comparison, and SNPstats software for comparison. The whole genome SNP analysis of Mycoplasma pneumoniae finally screened out 1401 candidate SNP sites.
Embodiment 2
[0030] Example 2 Verification of SNP site discrimination ability
Embodiment 1
[0031] The 1401 sites screened in Example 1 can be clustered into two groups ( figure 1 ), which correspond to traditional types 1 and 2 of Mycoplasma pneumoniae, respectively. Foreign literature reports also have the same results, which shows that most of the SNP sites in Mycoplasma pneumoniae are actually associated with traditional types 1 and 2. Therefore, when selecting SNP sites for distinguishing ability, type 1 and type 2 strains should be separated. Screening after separation to avoid mixing the SNPs screened can actually only distinguish traditional type 1 and type 2.
[0032] In the 69 Mycoplasma pneumoniae whole-genome sequencing strains, the SNP site discrimination ability was calculated according to the traditional type 1 and 2 genotypes, and the sites with polymorphisms less than 1% were not considered as SNP sites, but as mutation sites point. There are many sites that can be selected in the present invention. In order to obtain greater discrimination ability...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


